Skip to content
Welcure Drugs & Pharmaceuticals logo

Welcure Drugs & Pharmaceuticals

524661 BSE
₹0.18

Close ·

P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹0.18 −0.35 −66.0% 1Y
Start ₹0.53

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
−3.40%
Debt to Equity
0.00
EPS (TTM)
−₹0.13
Book Value
₹0.79
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
0.23
ROE
−5.50%
Dividend Yield
0.00%
EBITDA
−₹6.93 Cr
52W High
₹0.64
52W Low
₹0.17

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

56 Good

Data confidence 88/100

Category scores

Quality
55
Good
Returns, margins, earnings quality 22% weight
Valuation
72
Strong
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
44
Weak
Solvency, leverage, coverage 9% weight
Momentum
7
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 0.25 times its book value

Weaknesses

3
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -2.28% over last 3 years.
  • Company has high debtors of 213 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1261
OscillatorsBearish261
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
37.88
Neutral
MACD (12,26,9)
−0.01
Bearish
SMA (50)
0.21
Bearish
SMA (200)
0.27
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
10YZero base
5YZero base
3YZero base
1YTiny base

Net profit

Net profit growth by window
10YTurned to loss
5YTurned to loss
3YTurned to loss
1YTurned to loss

Operating cash flow

Operating cash flow growth by window
10YZero base
5YZero base
3YZero base
1YTurned positive

Operating margin· change in pp

Operating margin growth by window
10YNo sales
5YNo sales
3YNo sales
1Y−5.91 pp

Trailing twelve months: The last four quarters end with the latest fiscal year, which the 1Y column covers.

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹0.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹0.00 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹25.00 Cr
Mar 2026₹366 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹0.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹0.00 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹2.00 Cr
Mar 2026−₹5.00 Cr

Quarterly Results

₹ Cr

Results for the period ended Jun 2026 were due by 14 Aug 2026 and are not in this table yet.

524661 quarterly results, ₹ crore
Particulars Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
0
0
0
0
0
0
25
1
21
300
66
0
0
Expenses
0
0
0
0
0
0
23
1
21
269
54
0
50
Operating Profit
0
0
0
0
0
0
2
0
1
31
11
0
−50
OPM %
—
—
—
—
—
—
7%
10%
3%
10%
17%
—
—
Other Income
0
0
0
0
0
0
0
0
2
0
0
1
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
0
0
2
0
3
31
11
1
−50
Tax %
0%
0%
0%
0%
0%
0%
0%
56%
0%
25%
25%
25%
0%
Net Profit
0
0
0
0
0
0
2
0
3
23
8
1
−50
EPS (₹)
0.01
0
−0.01
0
0
−0.02
0.01
0
0.02
0.19
0.07
0.01
−0.4

Profit & Loss

₹ Cr
524661 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
0
0
0
0
0
0
0
0
0
0
25
366
Expenses
0
0
0
0
0
0
0
0
0
0
24
372
Operating Profit
0
0
0
0
0
0
0
0
0
0
1
−7
OPM %
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
—
—
4%
−1.9%
Other Income
0
0
0
0
0
0
0
0
0
0
2
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
0
0
0
0
0
0
3
−5
Tax %
0%
0%
0%
0%
—
0%
0%
0%
0%
0%
22%
0%
Net Profit
0
0
0
0
0
0
0
0
0
0
2
−5
EPS (₹)
0
0.01
0
0
0
0
0
0
0.01
−0.01
0.02
−0.04
Div. Payout %
0%
0%
0%
0%
—
0%
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
524661 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
12
12
12
12
12
12
12
12
13
13
112
124
Reserves
−12
−12
−12
−12
−12
−12
−12
−12
−12
−12
−10
−27
Borrowings
0
0
0
0
0
0
0
0
0
0
123
0
Other Liabilities
0
0
0
0
0
0
0
0
0
0
41
413
Total Liabilities
0
0
0
0
0
0
0
0
2
1
267
510
Fixed Assets
0
0
0
0
0
0
0
0
0
0
0
0
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
1
Other Assets
0
0
0
0
0
0
0
0
1
1
267
509
Total Assets
0
0
0
0
0
0
0
0
2
1
267
510

Cash Flow

₹ Cr
524661 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
0
0
0
0
0
0
0
0
0
−222
2
Investing
0
0
0
0
0
0
0
0
0
0
0
−1
Financing
0
0
0
0
0
0
0
0
0
0
222
0
Net Cash Flow
0
0
0
0
0
0
0
0
0
0
0
0
Free Cash Flow
0
0
0
0
0
0
0
0
0
0
−222
2
CFO/OP
100
−125
67
50
—
100
67
100
−79
57
−22,890
−25

Ratios

524661 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
—
—
—
—
—
—
—
—
—
282
213
Inventory Days
—
—
—
—
—
—
—
—
—
—
2,554
162
Days Payable
—
—
—
—
—
—
—
—
—
—
52
226
Cash Conversion Cycle
—
—
—
—
—
—
—
—
—
—
2,784
150
Working Capital Days
—
—
—
—
—
—
—
—
—
—
2,092
−56
ROCE %
—
—
120%
−67%
0%
−40%
133%
25%
10%
−13%
3%
−3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Welcure Drugs & Pharmaceuticals insights

59 extracted metrics across FY10–FY26.

Shareholding Pattern

As of Mar 2026

  • Public 95.63%
  • Others 4.37%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Welcure Drugs & Pharmaceuticals

What does Welcure Drugs & Pharmaceuticals Ltd do?
Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.
Where is Welcure Drugs & Pharmaceuticals Ltd (WELCURE) listed?
Welcure Drugs & Pharmaceuticals Ltd trades under code 524661 on the BSE.
Which sector does Welcure Drugs & Pharmaceuticals Ltd belong to?
Welcure Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Welcure Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Welcure Drugs & Pharmaceuticals Ltd has traded between ₹0.17 and ₹0.64 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Welcure Drugs & Pharmaceuticals Ltd?
Welcure Drugs & Pharmaceuticals Ltd reported a return on equity of -5.50%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1992, Welcure Drugs and Pharmaceuticals Ltd is in the business of pharmaceutical and healthcare.

Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524661.md for Welcure Drugs & Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month